Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial

BACKGROUND: The MITO-2 (Multicentre Italian Trials in Ovarian cancer) study is a randomized phase III trial comparing carboplatin plus paclitaxel to carboplatin plus pegylated liposomal doxorubicin in first-line chemotherapy of patients with ovarian cancer. Due to the paucity of published phase I da...

Descripción completa

Detalles Bibliográficos
Autores principales: Pignata, Sandro, Scambia, Giovanni, Savarese, Antonella, Breda, Enrico, Scollo, Paolo, De Vivo, Rocco, Rossi, Emanuela, Gebbia, Vittorio, Natale, Donato, Del Gaizo, Filomena, Naglieri, Emanuele, Ferro, Antonella, Musso, Pietro, D'Arco, Alfonso Maria, Sorio, Roberto, Pisano, Carmela, Di Maio, Massimo, Signoriello, Giuseppe, Annunziata, Annalisa, Perrone, Francesco
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1553473/
https://www.ncbi.nlm.nih.gov/pubmed/16882344
http://dx.doi.org/10.1186/1471-2407-6-202

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1553473/
https://www.ncbi.nlm.nih.gov/pubmed/16882344
http://dx.doi.org/10.1186/1471-2407-6-202

Ejemplares similares